{"url_path":"/sec/gctk/8-k/2026-07-15/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-033393-index.html","accession_number":"0001493152-26-033393","cik":"0001506983","ticker":"GCTK","issuer_name":"Glucotrack, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1506983/0001493152-26-033393-index.html","primary_entity_key":"0001506983","primary_entity_name":"Glucotrack, Inc."},"word_count":559,"has_tables":true,"body_markdown":"** **\n\n**Item\n5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of\nCertain Officers.**\n\n** **\n\nThe\ndisclosure set forth above in Item 1.01 of this Current Report on Form 8-K in the section titled “*Changes to the Board of Directors\nand Management*” is incorporated into this Item 5.02 by reference.\n\n \n\nOn\nJuly 9, 2026, the Acquiror Board expanded the size of the Board from five (5) members to six (6) members, effective upon the Closing,\nand appointed Erik Emerson to fill the vacancy created by such expansion, effective upon the Closing.\n\n \n\nThere\nare no family relationships between Erik Emerson and any of the Acquiror’s other officers and directors. Except as provided in\nthe Merger Agreement, there are no arrangements or understandings between Mr. Emerson and other persons pursuant to which he was selected\nas a director of the Acquiror. Mr. Emerson has not engaged in any transaction with the Acquiror that would be reportable as a\nrelated party transaction under Item 404(a) of SEC Regulation S-K.\n\n \n\nErik\nEmerson, age 55, is a 25-year veteran of the biopharmaceutical industry. Mr. Emerson previously served as Chief Executive Officer\nof Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) from September 2023 to December 2025, and as a director of the company\nfrom October 2024 to January 2026. Mr. Emerson was appointed Chief Executive Officer of Lokahi Therapeutics Inc. in December 2025. From\nAugust 2022 to October 2023, Mr. Emerson has served as Chief Commercial Officer of Odyssey Neuropharma, Inc., where he lead commercial\nstrategy, forecasting, branding, marketing, and financing efforts for a Phase II asset in evaluation for the treatment of mild\ntraumatic brain injury (concussion). He has also served as an advisory board member to NuGen Medical Devices from August 2022 to May\n2023, and as a Partner at Pharmacense Consulting from May 2020 to October 2023. Mr. Emerson served as Chief Commercial Officer\nof Mezzion Pharmaceuticals, a Korean company establishing U.S. operations for the treatment of Single Ventricle\nHeart Disease following Fontan surgery, from February 2017 to January 2020. During an overlapping period, from February 2018\nto November 2019, he served as Chief Commercial Officer and a board member of Adhera Therapeutics (previously known as\nMarina Biotech). Concurrently, from July 2017 to November 2019, he served as Executive Chairman and Chief Executive Officer of BioMauris\nLLC, a software entity he founded to track medicinal marijuana products from seed to sale, built on technology adapted from his prior\nventure, Symplmed. Prior to founding BioMauris, Mr. Emerson served as President and Chief Executive Officer of Symplmed Pharmaceuticals\n& Technologies from July 2013 to May 2018. From May 2010 to July 2013, he served as Senior Director of Commercial Development\nat Xoma Ltd. He was the Director of Marketing, Cardiopulmonary Division, at Gilead Sciences from May 2007 to May 2010. Mr.\nEmerson began his career in sales, sales training, and marketing with King Pharmaceuticals from May 2001 to May 2007,\nultimately serving as Senior Product Manager – Cardiometabolic. Mr. Emerson received a Bachelor of Science in Political\nScience from the University of Oregon in 1993. The Acquiror Board believes that Mr. Emerson’s experience in the biopharmaceutical\nindustry, including his prior service as a chief executive officer, chief commercial officer, and board member at multiple life sciences\ncompanies, qualifies him to serve on the board of directors of the Acquiror."}